CalciMedica CEO granted 148,482 stock options

CalciMedica, Inc. director and chief executive officer Rachel A. Leheny received a grant of 148,482 employee stock options to buy common stock at an exercise price of $0.585 per share.

Rhea-AI Filing Summary

CalciMedica, Inc. director and chief executive officer Rachel A. Leheny received a grant of 148,482 employee stock options to buy common stock at an exercise price of $0.585 per share. The options expire on April 4, 2036.

Beginning April 1, 2026, 1/48th of the shares subject to the option vest in equal monthly installments over four years. No shares will vest until a Form S-8 is filed for shares automatically added to the company’s 2023 Equity Incentive Plan on January 1, 2026.

Insider Trade Summary

Grant/Award: 148,482 shares

Grant/Award 1 txn

Insider Leheny A. Rachel

Role CHIEF EXECUTIVE OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (Right to Buy)	148,482	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (Right to Buy) — 148,482 contracts (Direct)

Footnotes (1)

1. F1. Beginning April 1, 2026, 1/48th of the shares subject to the option vest in equal monthly installments over a four year period, provided, however, that no shares shall vest until the filing of the Company's registration statement on Form S-8 covering the shares of Common Stock that were automatically added to the shares authorized for issuance under the Company's 2023 Equity Incentive Plan on January 1, 2026 pursuant to an annual "evergreen" provision.

Key Figures

Option grant size: 148,482 options Exercise price: $0.585 per share Total derivatives after grant: 148,482 options +3 more

6 metrics

Option grant size 148,482 options Employee Stock Option grant to CEO Rachel A. Leheny

Exercise price $0.585 per share Exercise price for the employee stock options

Total derivatives after grant 148,482 options Total derivative securities following transaction

Expiration date April 4, 2036 Option expiration for the granted stock options

Vesting commencement April 1, 2026 Start date for monthly vesting installments

Vesting rate 1/48th monthly Vesting schedule over four years

Key Terms

Employee Stock Option (Right to Buy), Equity Incentive Plan, evergreen provision, Form S-8, +1 more

5 terms

Employee Stock Option (Right to Buy) financial

"security_title: "Employee Stock Option (Right to Buy)""

Equity Incentive Plan financial

"under the Company's 2023 Equity Incentive Plan on January 1, 2026"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

evergreen provision financial

"pursuant to an annual "evergreen" provision"

An evergreen provision is a clause in a financing or contract that automatically renews or replenishes the arrangement unless one party actively cancels it, like a subscription that keeps renewing each term. For investors it matters because it creates predictable, ongoing access to funding or ongoing contractual obligations — helping liquidity and planning — but can also hide long-term commitments or dilution risks if not reviewed.

Form S-8 regulatory

"until the filing of the Company's registration statement on Form S-8"

A Form S-8 is a U.S. Securities and Exchange Commission registration that lets a public company set aside shares for employee benefit plans and stock-based compensation. Think of it as opening a dedicated account that authorizes the company to issue or reserve stock for workers and directors; it matters to investors because it enables share dilution when those awards are granted or exercised and signals how management is compensated and incentivized.

vesting financial

"1/48th of the shares subject to the option vest in equal monthly installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did CalciMedica (CALC) report in this Form 4?

CalciMedica reported a stock option grant to CEO and director Rachel A. Leheny for 148,482 options. These options give her the right to buy common stock at a fixed price, serving as equity-based compensation tied to the company’s future performance.

How many stock options did CalciMedica CEO Rachel Leheny receive?

Rachel Leheny received 148,482 employee stock options. Each option allows her to purchase one share of CalciMedica common stock. The grant represents a single equity award and is reflected as 148,482 derivative securities following the reported transaction.

What is the exercise price of the CalciMedica stock options granted?

The granted options have an exercise price of $0.585 per share. This means Rachel Leheny can purchase CalciMedica common stock at $0.585 if the options vest and are exercised before expiration, regardless of the future market price at that time.

When do Rachel Leheny’s CalciMedica options start vesting and on what schedule?

Vesting for the options begins on April 1, 2026. From that date, 1/48th of the 148,482 options vest monthly over four years, creating a gradual vesting schedule that links full ownership of the award to continued service over time.

Are there conditions that must be met before any of the CalciMedica options vest?

Yes. No shares will vest until CalciMedica files a Form S-8 covering shares automatically added on January 1, 2026, to the 2023 Equity Incentive Plan under its evergreen provision, creating a regulatory prerequisite before vesting can begin.

When do the newly granted CalciMedica stock options expire?

The options granted to Rachel Leheny expire on April 4, 2036. She may exercise vested options any time up to that expiration date, subject to plan terms and other applicable restrictions governing option exercises and insider trading compliance.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/07/2026 - 09:50 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Leheny A. Rachel

(Last) (First) (Middle)

C/O CALCIMEDICA, INC.

505 COAST BLVD. S. #307

(Street)

LA JOLLA CALIFORNIA 92037

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CalciMedica, Inc. [ CALC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF EXECUTIVE OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$0.585	04/05/2025		A		148,482		(1)	04/04/2036	Common Stock	148,482	$0	148,482	D

Explanation of Responses:

1. Beginning April 1, 2026, 1/48th of the shares subject to the option vest in equal monthly installments over a four year period, provided, however, that no shares shall vest until the filing of the Company's registration statement on Form S-8 covering the shares of Common Stock that were automatically added to the shares authorized for issuance under the Company's 2023 Equity Incentive Plan on January 1, 2026 pursuant to an annual "evergreen" provision.

	/s/ John Dunn, Attorney-in-Fact	04/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)